Urolithin A Gives HFpEF a New Molecular Target in Experimental Models
A compound made by the body after eating pomegranates, walnuts, and some berries improved heart function by up to 80% in experimental models of heart failure with preserved ejection fraction (HFpEF), a form of heart failure that remains difficult to treat because the heart still pumps but no longer relaxes properly. The work points to a new biological lever in a condition defined less by weak contraction than by stiffness, impaired filling, and progressive structural change in the myocardium.
HFpEF is common, debilitating, and stubbornly resistant to the therapies that transformed treatment for reduced-ejection heart failure. The heart muscle in this syndrome becomes less compliant, so filling pressures rise and exertional symptoms follow: shortness of breath, fatigue, and limited exercise tolerance. In practical bedside terms, patients can have a preserved ejection fraction on imaging and still live with serious heart failure symptoms because diastolic dysfunction is doing the damage.
The experimental compound, urolithin A, drew attention because it has already been linked to healthy aging and mitochondrial function. This study adds a more specific cardiovascular mechanism: urolithin A activates PKG1α, a protein involved in blood vessel function and heart muscle relaxation. Investigators identified action at a particular amino acid within the protein, triggering a pathway associated with improved cardiovascular performance.
Relaxation, Fibrosis, and Hypertrophy Shifted in the Same Direction
The most striking signal was functional. In animal models, treatment with urolithin A improved measures of heart function by as much as 80% compared with untreated controls. Separate laboratory experiments showed that the compound helped heart tissue relax more effectively, reduced fibrosis, and limited abnormal enlargement of heart muscle cells. Those findings matter because fibrosis stiffens the ventricle, while hypertrophy and remodeling make the chamber even less efficient at filling and emptying under physiologic stress.
A single sentence captures the therapeutic logic: the compound did not just nudge one biomarker, it shifted the remodeling program itself.
That pattern fits HFpEF biology. When the myocardium becomes infiltrated with scar and the cardiomyocytes enlarge, the ventricle loses compliance and the pressure-volume relationship worsens. Any agent that can improve relaxation while limiting scar formation and cellular enlargement has, at least in theory, a chance to blunt the structural spiral that keeps HFpEF entrenched.
The study also matters because it connects a dietary metabolite to a defined signaling node rather than to a vague wellness claim. Urolithin A is not being proposed here as a cure based on food alone. The biologic story is more precise: metabolism of certain foods generates a compound that can engage a protein pathway tied to myocardial relaxation and vascular function.
Engineered Human Heart Tissue Matched the Direction of Effect
The researchers did not stop with animal work. They also tested urolithin A in engineered human heart tissue derived from human stem cells, a model designed to mimic the structure and behavior of human myocardium more closely than a standard cell culture system. In that platform, urolithin A significantly improved relaxation.
That result is important because HFpEF therapies often falter when findings do not hold up outside rodent physiology. The engineered tissue data do not prove clinical efficacy, but they do reduce the chance that the mechanism is purely species-specific. A drug that improves relaxation in human-derived tissue while also reducing fibrosis in animal models has a stronger translational profile than a compound that only looks active in one experimental setting.
Urolithin A also stands apart from many early-stage candidates because it has already been evaluated in humans and has shown a favorable safety profile. Safety alone does not establish efficacy, but it does lower one of the major barriers to future development. A compound with existing human exposure history can move through the translational pipeline with fewer unknowns than a first-in-class molecule starting from scratch.
Why HFpEF Has Been So Hard to Move
HFpEF accounts for roughly half of all heart failure cases and is driven by multiple overlapping contributors, including aging, high blood pressure, and diabetes. That complexity is one reason standard heart failure therapies have often delivered less dramatic benefit than they do in reduced-ejection disease. The syndrome is not a single disease process; it is a convergent phenotype in which vascular stiffness, metabolic dysfunction, inflammation, and myocardial remodeling all feed into impaired filling.
Dr. Joseph Burgoyne, the senior author, described the condition as increasingly common as populations age and rates of obesity and diabetes rise. The statement tracks with the pathophysiology seen at the bedside. As comorbidity burden increases, the ventricle is exposed to repeated metabolic and hemodynamic stress, and the stiffening process becomes harder to reverse.
Professor James Leiper of the British Heart Foundation placed the findings in the same frame, noting that the early-stage work suggests urolithin A may improve the heart tissue’s ability to relax and fill with blood between beats. He also emphasized the key limitation: the benefits so far have been seen in animals and engineered human tissue, so clinical trials in people are still needed.
Pomegranates Are Not the Prescription
The dietary origin of urolithin A invites easy overinterpretation, but the investigators were explicit about the boundary. There is not enough evidence to suggest that people should eat pomegranates to treat heart failure. Human metabolism, gut microbiota composition, and dietary exposure all vary too much for that leap.
Still, the biology is provocative. If a naturally derived metabolite can activate PKG1α and improve relaxation while reducing scar and hypertrophic remodeling, it could open two paths at once: a direct therapeutic strategy and a way to understand which patients might benefit from pathway-targeted treatment. Future work will need to determine whether the effect translates into measurable clinical outcomes, which dose is required, how much inter-individual variation exists in urolithin A production, and whether the signal holds across the heterogeneous HFpEF population.
For now, the study stops at the edge of clinical application. The most immediate consequence is not a change in prescribing, but a clearer map of where HFpEF biology may still be vulnerable: the machinery that governs relaxation, fibrosis, and myocardial remodeling. The next test is whether that molecular opening exists in patients, not just in experimental hearts.
The study was published in Science Advances and funded by the British Heart Foundation.